Comments
Amgen to pay $762 million, pleads guilty in marketing case
19.12.2012. | NEW YORK (Reuters) - Amgen Inc pleaded guilty in a New York federal court on Tuesday for improper marketing practices involving its once top-selling Aranesp anemia drug, and prosecutors said the company has agreed to pay $762 million in a civil settlement and criminal fines....
